Regardless of the potential of TRAIL as a promising cancer therapeutic agent, soluble human TRAIL clinical applications have been hampered due to its weak pharmacokinetic profile, extremely poor circulation and short serum half-life, rapid renal elimination, insufficient delivery to the target site and TRAIL resistance in some cancer cells10–12. Here, TNFSF10 is linked to cancer.